论文部分内容阅读
目的探讨硫普罗宁与多烯磷脂酰胆碱联合治疗酒精性肝病(alcoholic liver disease,ALD)患者的临床疗效。方法将2012年6月—2014年4月收治的148例ALD患者随机分为治疗组和对照组,每组74例。治疗组予硫普罗宁和多烯磷脂酰胆碱治疗,400 mg硫普罗宁加入到5%的250 ml葡萄糖中进行静脉滴注治疗,1次/d,465 mg多烯磷脂酰胆碱进行口服治疗,3次/d,疗程两个月,对照组予基础护肝治疗。观察两组患者治疗前后的ALT、AST、GGT、TBIL、TG与TC水平变化情况,计量资料以±s表示,采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果治疗后,治疗组和对照组的ALT、AST、GGT、TBIL、TG与TC水平[(42.1±14.7)、(99.6±27.8)、(51.6±29.7)、(130.5±38.1)、(61.7±29.8)、(124.0±36.3)U/L、(19.3±8.9)、(30.2±9.7)、(3.3±0.6)、(5.6±0.9)、(2.4±0.9)、(4.62±0.6)mmol/L]均低于治疗前[(179.8±68.5)、(170.4±72.6)、(229.3±82.9)、(237.3±76.8)、(172.5±69.7)、(219.3±72.5)U/L、(60.2±18.4)、(62.7±12.9)、(8.4±1.4)、(7.9±1.1)、(5.69±1.3)、(5.73±1.2)mmol/L],且治疗组低于对照组,差异均有统计学意义(均P<0.05)。结论硫普罗宁与多烯磷脂酰胆碱联合治疗ALD可明显改善患者肝功能,安全有效,值得广泛应用。
Objective To investigate the clinical efficacy of tiopronin and polyene phosphatidylcholine in the treatment of patients with alcoholic liver disease (ALD). Methods A total of 148 ALD patients admitted from June 2012 to April 2014 were randomly divided into treatment group and control group, with 74 cases in each group. The treatment group was given tiopronin and polyene phosphatidylcholine treatment, 400 mg tiopronin was added to 5% of 250 ml of glucose for intravenous drip treatment, 1 / d, 465 mg of polyene phosphatidylcholine for oral Treatment, 3 times / d, course of treatment for two months, the control group to basic protection of liver treatment. The changes of ALT, AST, GGT, TBIL, TG and TC before and after treatment were observed. The measurement data were expressed as ± s. The t test was used to count data and the χ2 test was used to count the data. The difference was statistically significant at P <0.05. Results After treatment, the levels of ALT, AST, GGT, TBIL, TG and TC in the treatment group and control group [(42.1 ± 14.7), (99.6 ± 27.8), (51.6 ± 29.7), (130.5 ± 38.1), (61.7 ± 29.8, 124.0 ± 36.3 U / L, 19.3 ± 8.9, 30.2 ± 9.7, 3.3 ± 0.6, 5.6 ± 0.9, (2.4 ± 0.9), (4.62 ± 0.6) mmol / L ] Were lower than those before treatment [(179.8 ± 68.5), (170.4 ± 72.6), (229.3 ± 82.9), (237.3 ± 76.8), (172.5 ± 69.7), (219.3 ± 72.5) U / ), (62.7 ± 12.9), (8.4 ± 1.4), (7.9 ± 1.1), (5.69 ± 1.3) and (5.73 ± 1.2) mmol / L, respectively. The difference between the two groups was statistically significant (All P <0.05). Conclusion The combination of tiopronin and polyene phosphatidylcholine in the treatment of ALD can improve the liver function of patients, which is safe and effective and should be widely used.